Compare Sterling Biotech with GSK Pharma - Equitymaster

Helping You Build Wealth With Honest Research
Since 1996. Try Now

  • MyStocks

MEMBER'S LOGINX

     
Login Failure
   
     
   
     
 
 
 
(Please do not use this option on a public machine)
 
     
 
 
 
  Sign Up | Forgot Password?  

STERLING BIOTECH vs GSK PHARMA - Comparison Results

STERLING BIOTECH     Change

Sterling Biotech primarily produces and distributes pharmaceutical grade gelatine globally. The company currently has a 7.5% share of the global market for pharmaceutical and nutraceutical gelatines. It has more than 70% market share in India. Sterli... More

GSK PHARMA 
   Change

GSK Pharma is one of the leading MNC pharma companies in the Indian market. It is a 50.7% subsidiary of GlaxoSmithKline Plc, one of the world's largest pharma companies. GSK Pharma's product portfolio boasts of some of the leading brands like Augment... More

DO YOU LIKE THESE REPORTS? TELL US!

Current Valuations

    STERLING BIOTECH GSK PHARMA STERLING BIOTECH/
GSK PHARMA
 
P/E (TTM) x -0.4 52.3 - View Chart
P/BV x 0.0 11.0 0.1% View Chart
Dividend Yield % 0.0 1.4 -  

Financials

 STERLING BIOTECH   GSK PHARMA
EQUITY SHARE DATA
    STERLING BIOTECH
Dec-13
GSK PHARMA
Mar-19
STERLING BIOTECH/
GSK PHARMA
5-Yr Chart
Click to enlarge
High Rs113,595 0.3%   
Low Rs31,253 0.3%   
Sales per share (Unadj.) Rs26.8184.7 14.5%  
Earnings per share (Unadj.) Rs-15.026.3 -56.9%  
Cash flow per share (Unadj.) Rs-5.529.2 -18.7%  
Dividends per share (Unadj.) Rs020.00 0.0%  
Dividend yield (eoy) %00.8 0.0%  
Book value per share (Unadj.) Rs54.9126.3 43.4%  
Shares outstanding (eoy) m267.87169.40 158.1%   
Bonus/Rights/Conversions ---  
Price / Sales ratio x0.313.1 2.0%   
Avg P/E ratio x-0.592.2 -0.5%  
P/CF ratio (eoy) x-1.383.1 -1.5%  
Price / Book Value ratio x0.119.2 0.7%  
Dividend payout %076.1 0.0%   
Avg Mkt Cap Rs m1,862410,626 0.5%   
No. of employees `0001.45.0 27.3%   
Total wages/salary Rs m5475,372 10.2%   
Avg. sales/employee Rs Th5,303.36,306.7 84.1%   
Avg. wages/employee Rs Th403.81,083.1 37.3%   
Avg. net profit/employee Rs Th-2,959.0898.0 -329.5%   
INCOME DATA
Net Sales Rs m7,18131,281 23.0%  
Other income Rs m431,023 4.2%   
Total revenues Rs m7,22332,304 22.4%   
Gross profit Rs m9476,009 15.8%  
Depreciation Rs m2,543486 523.3%   
Interest Rs m4,3776 72,951.7%   
Profit before tax Rs m-5,9316,540 -90.7%   
Minority Interest Rs m00-   
Prior Period Items Rs m00-   
Extraordinary Inc (Exp) Rs m0287 0.0%   
Tax Rs m-1,9242,373 -81.1%   
Profit after tax Rs m-4,0074,454 -90.0%  
Gross profit margin %13.219.2 68.6%  
Effective tax rate %32.436.3 89.4%   
Net profit margin %-55.814.2 -391.9%  
BALANCE SHEET DATA
Current assets Rs m14,33520,061 71.5%   
Current liabilities Rs m49,80914,543 342.5%   
Net working cap to sales %-494.017.6 -2,800.5%  
Current ratio x0.31.4 20.9%  
Inventory Days Days40357 710.5%  
Debtors Days Days17114 1,213.7%  
Net fixed assets Rs m55,43214,343 386.5%   
Share capital Rs m2681,694 15.8%   
"Free" reserves Rs m13,93519,704 70.7%   
Net worth Rs m14,70121,398 68.7%   
Long term debt Rs m9,4782 473,892.5%   
Total assets Rs m73,98839,113 189.2%  
Interest coverage x-0.41,091.0 -0.0%   
Debt to equity ratio x0.60 689,771.0%  
Sales to assets ratio x0.10.8 12.1%   
Return on assets %0.511.4 4.4%  
Return on equity %-27.320.8 -130.9%  
Return on capital %-6.431.9 -20.1%  
Exports to sales %25.90-   
Imports to sales %0.20-   
Exports (fob) Rs m1,860NA-   
Imports (cif) Rs m12NA-   
Fx inflow Rs m1,860534 348.3%   
Fx outflow Rs m257,091 0.4%   
Net fx Rs m1,835-6,557 -28.0%   
CASH FLOW
From Operations Rs m1,7193,994 43.0%  
From Investments Rs m-3,148-1,433 219.6%  
From Financial Activity Rs m1,426-3,584 -39.8%  
Net Cashflow Rs m-3-1,023 0.3%  

Share Holding

Indian Promoters % 33.9 0.0 -  
Foreign collaborators % 0.0 50.7 -  
Indian inst/Mut Fund % 0.0 10.2 -  
FIIs % 9.9 23.8 41.6%  
ADR/GDR % 16.9 0.0 -  
Free float % 39.3 15.4 255.2%  
Shareholders   21,482 102,036 21.1%  
Pledged promoter(s) holding % 55.9 0.0 -  
NM: Not Meaningful
Source: Company Annual Reports, Regulatory Filings, Equitymaster

Compare STERLING BIOTECH With:   ALEMBIC LTD  AUROBINDO PHARMA  PIRAMAL ENTERPRISES  FDC LTD.  SUN PHARMA  

Compare STERLING BIOTECH With:   ACTAVIS (US)  MYLAN (US)  ADCOCK INGRAM (S. Africa)  TEVA PHARMA (Israel)  



Today's Market

Sensex Trades Marginally Higher; Tata Steel & Bajaj Finance Top Gainers(12:30 pm)

Share markets in India are presently trading on a positive note, tracking gains in global peers. US President Donald Trump said he did not want war.

Related Views on News

GSK PHARMA Announces Quarterly Results (1QFY20); Net Profit Up 28.1% (Quarterly Result Update)

Jul 24, 2019 | Updated on Jul 24, 2019

For the quarter ended June 2019, GSK PHARMA has posted a net profit of Rs 1 bn (up 28.1% YoY). Sales on the other hand came in at Rs 8 bn (up 7.1% YoY). Read on for a complete analysis of GSK PHARMA's quarterly results.

GSK PHARMA 2018-19 Annual Report Analysis (Annual Result Update)

Jun 24, 2019 | Updated on Jun 24, 2019

Here's an analysis of the annual report of GSK PHARMA for 2018-19. It includes a full income statement, balance sheet and cash flow analysis of GSK PHARMA. Also includes updates on the valuation of GSK PHARMA.

GSK PHARMA Announces Quarterly Results (4QFY19); Net Profit Up 16.6% (Quarterly Result Update)

May 21, 2019 | Updated on May 21, 2019

For the quarter ended March 2019, GSK PHARMA has posted a net profit of Rs 1 bn (up 16.6% YoY). Sales on the other hand came in at Rs 8 bn (up 0.3% YoY). Read on for a complete analysis of GSK PHARMA's quarterly results.

GSK PHARMA Announces Quarterly Results (3QFY19); Net Profit Up 26.0% (Quarterly Result Update)

Feb 5, 2019 | Updated on Feb 5, 2019

For the quarter ended December 2018, GSK PHARMA has posted a net profit of Rs 1 bn (up 26.0% YoY). Sales on the other hand came in at Rs 8 bn (up 17.3% YoY). Read on for a complete analysis of GSK PHARMA's quarterly results.

GSK PHARMA Announces Quarterly Results (2QFY19); Net Profit Down 22.7% (Quarterly Result Update)

Oct 23, 2018 | Updated on Oct 23, 2018

For the quarter ended September 2018, GSK PHARMA has posted a net profit of Rs 1 bn (down 22.7% YoY). Sales on the other hand came in at Rs 8 bn (down 2.4% YoY). Read on for a complete analysis of GSK PHARMA's quarterly results.

More Views on News

Most Popular

Buying these Eight Stocks is Like Owning Your Own Business(Profit Hunter)

Sep 5, 2019

Everyone dreams of owning a business. Here is your chance.

7 Stocks to Buy in the Market Today(The 5 Minute Wrapup)

Sep 5, 2019

The stock market had a four-year bull run starting September 2013. Are we seeing a similar pattern now?

Buy these 7 Stocks if You Believe in India(The 5 Minute Wrapup)

Sep 12, 2019

News headlines predict gloom and doom for India these days. You should ignore them.

A Recession Proof Stock You Can Bet On(Profit Hunter)

Sep 10, 2019

Usually, the typical horizon period for my smallcap recommendations is 3 to 5 years. But if you ask me, this could be one business that you could own and pass on to future generations.

This Company Will Do Well Despite the Slowdown(The 5 Minute Wrapup)

Sep 11, 2019

How financial inclusion provides a big runway for this stock recommendation.

More

Get the Indian Stock Market's
Most Profitable Ideas

How To Beat Sensex Guide 2019
Get our special report, How to Beat Sensex Nearly 3X Now!
We will never sell or rent your email id.
Please read our Terms

STERLING BIOTECH SHARE PRICE


Nov 5, 2018 (Close)

TRACK STERLING BIOTECH

  • Track your investment in STERLING BIOTECH with Equitymaster's Portfolio Tracker. Set live price alerts, get research alerts and more. Get access now...
  • Add To MyStocks

MORE ON STERLING BIOTECH

STERLING BIOTECH 8-QTR ANALYSIS

COMPARE STERLING BIOTECH WITH

MARKET STATS